Project Details
Projekt Print View

The immunoproteasome inhibition as a novel therapeutic strategy for the treatment of colitis-associated cancer

Subject Area Gastroenterology
Term from 2021 to 2025
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 457407471
 
Final Report Year 2025

Final Report Abstract

During the founding period, as applied, we focused on the impact of immunoproteasome on the colonic inflammation and colitis-associated cancer. Moreover, the characterization of a novel L. acidophilus-derived proteasome inhibitor was performed in the second part of the project. The enzymatic activity of the immunoproteasome is implicated in a number of pathological disorders, including various inflammatory and autoimmune diseases and hematological malignancies. We were able to show that the TKO mice devoid of functional immunoproteasomes display reduced number of colonic tumors in the experimental model of AOM/DSS-induced carcinogenesis. Furthermore, TKO mice displayed marked defects in cytokines with pro-inflammatory properties such as IL-17A, IL-6, IL-1β and TNF-α, which are important players in the development of inflammatory diseases. We were capable of demonstrating that an elevated production of pro-tumorigenic cytokines TNF-α, IL-6 and IL-17A, as well as recruitment of pro-inflammatory leukocytes to the colon, are mechanistically connected to the increased enzymatic activity of immunoproteasomes. Collectively, the inhibition of the immunoproteasome and its chymotrypsin-like activity in immune cells might be an innovative strategy in the therapy of ulcerative colitisassociated cancer.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung